DIHYDREXIDINE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H17NO2
Molecular Weight	267.3224
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=C(O)C=C2[C@H]3[C@H](CCC2=C1)NCC4=CC=CC=C34

InChI

InChIKey=BGOQGUHWXBGXJW-YOEHRIQHSA-N

InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H17NO2
Molecular Weight	267.3224
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9703756 | https://www.ncbi.nlm.nih.gov/pubmed/17596915 | https://www.ncbi.nlm.nih.gov/pubmed/15492773 | https://www.ncbi.nlm.nih.gov/pubmed/1352553

Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. Dihydrexidine was shown to stimulate cyclic AMP synthesis just as well or better than dopamine. It was the first dopamine D1 receptor agonist that had potent antiparkinsonian activity in a primate model of Parkinson's disease. Dihydrexidine produces hypothermia. Dihydrexidine has been shown to alleviate cognitive deficits or enhance cognitive performance in a number of animal models of cognition. It is under investigation for the improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D1 receptor 106 Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8100195\|https://www.ncbi.nlm.nih.gov/pubmed/2572425\|https://www.ncbi.nlm.nih.gov/pubmed/1680717	Agonist 2752		7.2 nM [EC50]

PubMed

Title	Date	PubMed
Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.	2011-08-11	21714510
Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.	2005-10	15985612
Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.	2004-02	15075630
A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?	2004	14960337
Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase.	2002-09-15	12223546
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.	2001-02	11160877

Patents

Sample Use Guides

In Vivo Use Guide

20 mg over 15 min

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:33:21 GMT 2025` Edited by `admin` on `Mon Mar 31 21:33:21 GMT 2025`
Record UNII	32D64VH037
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENZO(A)PHENANTHRIDINE-10,11-DIOL, 5,6,6A,7,8,12B-HEXAHYDRO-, HYDROCHLORIDE (1:1), (6ARS,12BSR)-, (±)-

Preferred Name

English

DIHYDREXIDINE

Common Name

English

BENZO(A)PHENANTHRIDINE-10,11-DIOL, 5,6,6A,7,8,12B-HEXAHYDRO-, HYDROCHLORIDE (1:1), (6AR,12BS)-REL-

Systematic Name

English

BENZO(A)PHENANTHRIDINE-10,11-DIOL, 5,6,6A,7,8,12B-HEXAHYDRO-, TRANS-

Common Name

English

REL-(6AR,12BS)-5,6,6A,7,8,12B-HEXAHYDROBENZO(A)PHENANTHRIDINE-10,11-DIOL

Common Name

English

Code System Code Type Description

CAS

123039-93-0